Best Cell & Gene Therapy CDMOs in China
· updated as new inspection, certificate, and trial data enters the platform
8
CDMOs tracked
5
Fully scored
4
EMA/MHRA GMP certs
Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.
For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).
Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
83.7 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 2 |
GS
GenScript ProBio
Piscataway, NJ · Nanjing, CN
|
79.5 | 100.0 | — | Constrained | 0 programs |
| 3 |
GenScript
Piscataway, NJ (US HQ); Nanjing, China (primary operations)
|
65.5 | — | — | — | 0 programs |
| 4 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
60.5 | — | — | — | 0 programs |
| 5 |
CoJourney Inc.
Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)
|
60.0 | — | — | Limited | 0 programs |
| — |
Altruist Biologics
Suzhou, China
|
Profiled | — | — | Available | 0 programs |
| — |
Canton Biologics Co., Ltd.
Foshan (Shunde District), China
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics
Guangzhou, China
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Cell & Gene Therapy CDMO
Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.
How do the BioSecure Act and 1260H list affect Chinese CDMO selection for US programs?
US sponsors evaluating Chinese CDMOs currently face two active US regulatory considerations. The DoD 1260H list designates named Chinese companies as "Chinese Military Companies" — WuXi AppTec was added in June 2026. Listing itself doesn't restrict commercial pharma work but affects federally-funded research access and creates procurement complications for sponsors with government contracts. The BioSecure Act is proposed federal legislation that would restrict federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies (specifically BGI, MGI, Complete Genomics, WuXi AppTec, and WuXi Biologics as of current drafts). The bill has not passed as of 2026-08 but has bipartisan support. CDMO Signal does not encode US political risk into the Signal Score — the composite reflects regulatory quality, operations, financial stability, and capacity. Sponsors evaluating a Chinese CDMO for US-supplying programs should evaluate US regulatory risk separately as a distinct decision layer.
Chinese CDMOs with FDA and EMA inspection posture
Chinese CDMOs supplying US and European markets need active FDA and EMA GMP certifications on the specific facility. The FDA and EMA both conduct facility inspections in China, and Chinese CDMOs' inspection outcomes have generally improved over the past decade. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly. Chinese CDMOs with cross-jurisdictional certification rank higher on this pillar than domestic-market-only competitors. Cross-check with the US region ranking — Chinese CDMOs appearing on both rankings have demonstrated cross-jurisdictional inspection posture, which materially reduces regulatory risk for programs supplying US markets.
Which modality classes have the strongest Chinese CDMO capability?
China's CDMO capability is strongest in biologics (both mAb and biosimilar), viral vectors (particularly AAV, with substantial commercial-scale capacity via WuXi Advanced Therapies and others), and mRNA (rapid post-COVID capacity build). Small molecule and API manufacturing capacity is also substantial but sits outside CDMO Signal's primary coverage focus. Cross-reference with modality pages to filter Chinese CDMOs by capability: biologics, AAV, mRNA, or the viral vector umbrella. Individual profile pages surface facility-level detail.
Cell & Gene Therapy CDMOs — Frequently Asked Questions
Who are the top Cell & Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Cell & Gene Therapy CDMOs include WuXi Biologics, GenScript ProBio, GenScript. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 0 Cell & Gene Therapy CDMOs with FDA inspection records and 4 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
109 CDMOs are tracked as cell or gene therapy manufacturers — the union of cell therapy, AAV, lentiviral, adenoviral, and gene therapy-tagged CDMOs. This is the broadest advanced-therapy candidate list on our platform.
Related modalities